Gene Therapy improves functional measures in XLRP
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Search
Search results
From isolation to exploration
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
A new approach to treating inherited sight loss
A new approach to treating inherited sight loss
From isolation to exploration: what you can do to build your confidence when travelling
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
Potential drug targets identified for RP
A recently published study has described numerous disease mechanisms that appear to be common across different types of inherited sight loss, suggesting that there is significant potential for drug treatments that could work regardless of the underlying causative gene.
Webinar: Influencing with Retina UK
The latest webinar from Retina UK.
Flipping the switch on RP: SparingVision doses patients in their first in-human clinical trial for SPVN20
The latest research news from Retina UK.
Slowing sight loss in stargardts: Ocugen’s gene therapy trial offers promising early results
Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.
SparingVision completes dosing in PRODYGY trial of SPVNO6 for retinitis pigmentosa.
SparingVision have announced this week that they have dosed all participants in their phase 1/2 PRODYGY clinical trial for SPVN06, a gene agnostic therapy aimed at slowing disease progression in Retinitis Pigmentosa (RP).
Ocugen completes dosing of GARDian3 trial for OCU410ST ahead of schedule
Ocugen have recently announced that they have completed enrolment and dosing in their pivotal phase 2/3 trial of OCU410ST ahead of schedule.